PRESS RELEASE




INNATE PHARMA TO PARTICIPATE IN THE 2025 STIFEL
VIRTUAL TARGETED ONCOLOGY FORUM

Marseille, France, April 3, 2025, 7:00 AM CEST
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today
announced that members of its executive team will present and host 1x1 meetings at the Stifel
2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025.
The executive team will participate in a fireside chat scheduled on Wednesday, April 9, 2025,
from 12:30 - 12:55 p.m. ET.
A live webcast and a replay of the presentation will be available on the Events page in the
Investors section of Innate Pharma website.


About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing
immunotherapies for cancer patients. Its innovative approach aims to harness the innate
immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its
ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody
Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as
well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-
KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with
AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and
AstraZeneca, as well as leading research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on
Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.




Information about Innate Pharma shares

ISIN code FR0010331421
Ticker code Euronext: IPH Nasdaq: IPHA
LEI 9695002Y8420ZB8HJE29
PRESS RELEASE




Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the
meaning of applicable securities laws, including the Private Securities Litigation Reform Act of
1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and
similar expressions, is intended to identify forward-looking statements. Although the Company
believes its expectations are based on reasonable assumptions, these forward-looking
statements are subject to numerous risks and uncertainties, which could cause actual results
to differ materially from those anticipated. These risks and uncertainties include, among other
things, the uncertainties inherent in research and development, including related to safety,
progression of and results from its ongoing and planned clinical trials and preclinical studies,
review and approvals by regulatory authorities of its product candidates, the Company’s
reliance on third parties to manufacture its product candidates, the Company’s
commercialization efforts and the Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and uncertainties, which could cause the
Company's actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs
de Risque") section of the Universal Registration Document filed with the French Financial
Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org
or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and
Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the
year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC,
or otherwise made public by the Company. References to the Company’s website and the AMF
website are included for information only and the content contained therein, or that can be
accessed through them, are not incorporated by reference into, and do not constitute a part of,
this press release.

In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any specified time frame or at all.
The Company undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
PRESS RELEASE




For additional information, please contact:
Investors Media Relations

Innate Pharma NewCap
Henry Wheeler Arthur Rouillé
Tel.: +33 (0)4 84 90 32 88 Tel.: +33 (0)1 44 71 00 15
Henry.wheeler@innate-pharma.fr innate@newcap.eu